Loading...
Novel Fredericamycin Variant Overproduced by a Streptomycin-resistant subsp. Strain.
Rodríguez Estévez, Marta Myronovskyi, Maksym Rosenkränzer, Birgit Paululat, Thomas Petzke, Lutz Ristau, Jeanette Luzhetskyy, Andriy
Rodríguez Estévez, Marta
Myronovskyi, Maksym
Rosenkränzer, Birgit
Paululat, Thomas
Petzke, Lutz
Ristau, Jeanette
Luzhetskyy, Andriy
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2020-05-28
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 1.42 MB
Other Titles
Abstract
Streptomycetes are an important source of natural products potentially applicable in the pharmaceutical industry. Many of these drugs are secondary metabolites whose biosynthetic genes are very often poorly expressed under laboratory cultivation conditions. In many cases, antibiotic-resistant mutants exhibit increased production of natural drugs, which facilitates the identification and isolation of new substances. In this study, we report the induction of a type II polyketide synthase gene cluster in the marine strain Streptomyces albus subsp. chlorinus through the selection of streptomycin-resistant mutants, resulting in overproduction of the novel compound fredericamycin C2 (1). Fredericamycin C2 (1) is structurally related to the potent antitumor drug lead fredericamycin A.
Citation
Mar Drugs. 2020 May 28;18(6):284. doi: 10.3390/md18060284.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1660-3397
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International